Pre-reading

Severe tricuspid regurgitation (TR), whether symptomatic or asymptomatic, is predictive of poor survival if left untreated. Medical therapy, consisting mostly of diuretics, is of limited efficacy. Clinical sequelae, including right heart dysfunction, peripheral edema, and liver congestion, confer a poor quality of life and poor prognosis. Surgical tricuspid repair and replacement have significant mortality and morbidity risks due to patient comorbidities and poor right heart function.

Transcatheter tricuspid valve repair is an emerging alternative to medical therapy and surgery to manage patients with symptomatic severe TR. Several technologies are currently in clinical trials, including edge-to-edge repair, annuloplasty repair, and de novo replacement (Figure 1). The MitraClip device (Abbott Structural Heart; Santa Clara, CA) has been used to repair the tricuspid valve in an off-label manner in over 1,000 cases worldwide with excellent safety and good efficacy, as evidenced by multicenter retrospective studies and the TriValve Registry. The TRILUMINATE (Evaluation of Treatment With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater Tricuspid Regurgitation) global feasibility study, consisting of sites from the European Union and United States, evaluated transcatheter tricuspid valve repair using the TriClip system (Abbott Structural Heart; Santa Clara, CA). The 1-year outcomes, presented at the 2019 PCR London Valves Annual Meeting, showed excellent safety and efficacy of the TriClip system in terms of TR reduction, low mortality, improvement in quality of life, and right atrial and ventricular modeling (Figures 2-3).¹

^{Figure 1: Transcatheter Tricuspid Therapy Landscape}

^{Figure 2}

^{Figure 3}

^{Imaging the tricuspid valve can be challenging. Transesophageal echocardiography (TEE) is the primary modality used to optimize leaflet grasping and assessment of insertion (Figure 4). Intracardiac echocardiography (ICE) can be a valuable complementary imaging tool to confirm leaflet insertion (Figure 5).2 The TRILUMINATE Pivotal Trial is currently ongoing, randomizing patients with symptomatic severe TR to medical therapy or TriClip or utilizing TriClip as a treatment arm if the TR can be reduced by only one grade in severity.}

^{Figure 4}

^{Figure 5}

References

1. Nickenig G, on behalf of the TRILUMINATE investigators. Percutaneous edge-to-edge repair for tricuspid regurgitation: Initial 1-year outcomes from the TRILUMINATE clinical trial. Presented at PCR London Valves 2019; November 18, 2019.
2. Tang GH, Yakubov SJ, Sanchez Soto CE. Four-Dimensional Intracardiac Echocardiography in Transcatheter Tricuspid Valve Repair With the MitraClip System. JACC Cardiovasc Imaging 2020;Jan 9:[Epub ahead of print].